BIOMAT Database Logo BIOMAT Database Logo

Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. 1993

D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Monsanto Corporate Research, Medicinal Chemistry Department, St. Louis, Missouri 63167.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
July 1997, Journal of medicinal chemistry,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.
July 1992, Journal of medicinal chemistry,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
August 2020, Journal of medicinal chemistry,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease.
November 2003, Bioorganic & medicinal chemistry,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
March 1998, Bioorganic & medicinal chemistry letters,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
September 2000, Chemical & pharmaceutical bulletin,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere.
November 1991, Journal of medicinal chemistry,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
August 2005, Bioorganic & medicinal chemistry letters,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
October 2007, Bioorganic & medicinal chemistry letters,
D P Getman, and G A DeCrescenzo, and R M Heintz, and K L Reed, and J J Talley, and M L Bryant, and M Clare, and K A Houseman, and J J Marr, and R A Mueller
Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.
December 1998, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!